Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1562 plus rituximab in relapsed or refractory non-Hodgkin lymphoma
2015-004061-87Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naratuximab emtansine and rituximab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 3 more, sponsored by Debiopharm. Primary endpoint: Safety and tolerability. Started Jan 2016; status: completed.
02
Drugs
naratuximab emtansinerituximab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2015-004061-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004061-87.